MW 398.4 Da, Purity >99%. Selective cell-permeable inhibitor of casein kinase 1 (CK1). (IC50 values are 0.3 (CK1), 0.5 (ALK5), 9.1 (PKd1) and 5.8 μM (p38αMAPK)). Displays selectivity over many other protein kinases.
View Alternative Names
AAT 5, ACVRLK 4, ALK-5, Activin A receptor type II like kinase, Activin A receptor type II like kinase 53kDa, Activin A receptor type II like kinase, 53kD, Activin receptor-like kinase 5, CDC-like kinase 1, CDC28/CDC2 like kinase, CLK/STY, CLK1_HUMAN, CSAID Binding Protein 1, CSAID-binding protein, CSBP, CSBP 1, CSBP 2, CSPB1, Csaids binding protein, Cytokine suppressive anti-inflammatory drug-binding protein, Dual specificity protein kinase CLK1, EXIP, KPCD1_HUMAN, LDS1A, LDS2A, MAP kinase 14, MAP kinase MXI2, MAP kinase p38 alpha, MAPK 14, MAX-interacting protein 2, MK14_HUMAN, MSSE, Mitogen-activated protein kinase 14, Mitogen-activated protein kinase p38 alpha, Mxi 2, P38, PKC, PKC MU, PKCM, PKD, PRKCM, PRKD 1, PRKM14, PRKM15, Protein kinase C mu, Protein kinase C mu type, Protein kinase D, Protein kinase D1, Protein tyrosine kinase STY, RK, SAPK2A, SKR 4, STY, Serine/threonine-protein kinase D1, Serine/threonine-protein kinase receptor R4, Stress-activated protein kinase 2a, TGF-beta receptor type I, TGF-beta receptor type-1, TGF-beta type I receptor, TGFBR 1, TGFBR1 protein, TGFR1_HUMAN, TbetaR-I, Transforming growth factor beta receptor 1, Transforming growth factor beta receptor I, Transforming growth factor beta receptor I (activin A receptor type II like kinase, 53kD), Transforming growth factor-beta receptor type I, activin A receptor type II-like protein kinase of 53kD, nPKC-D1, nPKC-mu, p38 ALPHA, p38 MAP kinase, p38 MAPK, p38 mitogen activated protein kinase, p38alpha Exip
- FuncS
Unknown
Functional Studies - D4476, CK1 inhibitor (AB120220)
ab38511 staining βcatenin (phospho Thr42 + Ser45) in SK-N-SH cells treated with D4476 (ab120220), by ICC/IF. Decrease in expression of βcatenin (phospho Thr42 + Ser45) correlates with increased concentration of D4476, as described in literature.
The cells were incubated at 37°C for 2h in media containing different concentrations of ab120220 (D4476) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab38511 (5 μg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight® 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
- Chemical Structure
Lab
Chemical Structure - D4476, CK1 inhibitor (AB120220)
2D chemical structure image of ab120220, D4476, CK1 inhibitor
Properties and storage information
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
All these proteins play key roles in cellular communication and response modulation. p38 adjusts the cellular response to external stress signals and inflammation and it often forms part of larger signaling complexes. PKC mu/PKD regulates signal transduction pathways involved in cell proliferation and migration. TGF beta Receptor I mediates signaling for TGF-beta regulating cell growth and differentiation. CLK1 influences aspect of RNA splicing affecting gene expression and cellular metabolism.
Pathways
P38 MAPK signaling includes phosphorylation chains impacting cellular inflammatory response while closely interacting with proteins like MKK3 and MKK6. PKC mu/PKD signaling is integral to the DAG-activated pathway where it associates with proteins like Rac1. TGF beta Receptor I is critical for the TGF-beta signaling pathway interacting with SMAD proteins to transduce signals. CLK1 affects the CLK1 signaling pathway influencing RNA splicing through interactions with SR proteins.
Publications (6)
Recent publications for all applications. Explore the full list and refine your search
Iranian journal of basic medical sciences 26:1212-1219 PubMed37736507
2023
Applications
Unspecified application
Species
Unspecified reactive species
Bio-protocol 12: PubMed36353719
2022
Applications
Unspecified application
Species
Unspecified reactive species
Archivum immunologiae et therapiae experimentalis 69:26 PubMed34536148
2021
Applications
Unspecified application
Species
Unspecified reactive species
Science advances 7: PubMed33990333
2021
Applications
Unspecified application
Species
Unspecified reactive species
Scientific reports 6:34472 PubMed27681590
2016
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 5:5827 PubMed25500533
2014
Applications
Unspecified application
Species
Unspecified reactive species
Complementary Products
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com